CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and ...

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four ...

The RSUs are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a restricted stock unit agreement covering the grant. LENSAR is a commercial-stage ...

Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy® at a reduced price ...

Spartan Capital Securities, LLC is acting as exclusive placement agent for the private placement. TroyGould PC is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted ...

CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...

Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant. Akebia Therapeutics, Inc. is a ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation ...

ArriVent intends to use the net proceeds from the proposed offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for ...

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on June 30, 2025, the Company exchanged $6.5 million of its ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...